Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19 vaccine based on recombinant protein, which is being produced by Razi Vaccine and Serum Research Institute, Iran. This vaccine is the first injectable-intranasal recombinant protein corona vaccine.[1][2][3]It's the second Iranian COVID-19 vaccine reaching human trials[1] and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.[4][5]
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Routes of administration | Intramuscular, Intranasal |
Legal status | |
Legal status |
It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray).[3]
Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein.[2]
It's planned to produce one million doses of the vaccine each month as of September 2021.[4]
As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.[6]
Phase | Registration number | Start | Number of participants | Age of participants | Ref | ||
---|---|---|---|---|---|---|---|
Total | Vaccine | Placebo | |||||
I | IRCT20201214049709N1 | 21 January 2021 | 133 | 30 (5 µg/200µL)
30 (10 µg/200µL) 30 (20 µg/200µL) |
30 (placebo)
13 (sentinel) |
18-50 years | [2] |
II | IRCT20201214049709N2 | 13 April 2021 | 500 | 18-70 years | [3] | ||
III | IRCT20201214049709N3 | 29 August 2021 | 41,128 | 20,564 | 0 (placebo)
20,564 (Sinopharm BIBP vaccine) |
18+ years | [5] |